< Back to latest news & events

Articles

Can the Chancellor’s so-called “Europe’s Silicon Valley” really replicate the innovative activity of its namesake?

February 2025

The Chancellor of the UK, Rachel Reeves, recently unveiled plans to deliver an Oxford-Cambridge growth corridor that promises to boost the UK economy by up to £78 billion by 2035.  Declaring the UK as being at the “forefront of some of the most exciting developments in the world like artificial intelligence and life sciences”, she saw the 66 miles between Oxford and Cambridge as the “home of British innovation”, “with ingredients to replicate the success of Silicon Valley or the Boston Cluster”.

But how realistic are the Chancellor’s plans?

It’s relatively rare for the worlds of politics and Intellectual Property (IP) to collide. However, IP and, in particular, patent filings are often used as a barometer for innovation. As a rough and ready gauge of the Chancellor’s ambition, we’ve taken a look at how many artificial intelligence (AI) and life science (LS) patents have been filed by applicants in innovation hubs in Oxfordshire and Cambridgeshire and compared these numbers to those filed in the Silicon Valley and Boston Cluster.

A snapshot of our findings are summarised in the graphs below:

Data from IP Pilot; IPC codes: G06N and T

Data from IP Pilot; IPC codes: C12M, N, P, Q and R, A61K

Admittedly, these statistics are raw. Inaccuracies will arise for a variety of reasons. For example, if a patent for research carried out in e.g., Cambridge is filed in the name of a company registered elsewhere, our analysis will not have picked this up. Accordingly, the statistics must be taken with a large pinch of salt. Coupled with the differences in population between the areas compared, it’s clear that they do not provide an accurate comparison.

Nonetheless, the differences between the US and UK filing numbers are so great that it’s probably safe to say that the new growth corridor has a significant amount of catching up to do at least insofar as patenting in AI and LS is concerned. That said, the dominance of Silicon Valley and the Boston Cluster is hardly surprising as they’ve been well-funded and well-established hubs of innovation for a very long time.

Silicon Valley, for example, can trace its roots to an electrical company started in a garage by Standford alumni, William Hewlett and David Packard, in 1938[1].  Similarly, the Boston cluster can trace its roots to the late 1970s and early 80s, when Biogen and Genzyme were founded by scientists from nearby academic institutions[2]. So, in this context, the US has history on its side. Nonetheless, with the Chancellor’s promise to go “further and faster” to drive growth, the UK has the potential to improve its impact in the AI and LS fields. In any event, as we all know, numbers –particularly patent filing numbers – never tell the whole story and, as the old adage goes, quality always trumps quantity.

So what can the UK do to ensure that quality innovation boosts the economy in the manner we hope. Readers old enough to recall the VHS-Betamax[3] debate will know that it’s rarely the quality of the technology alone that will guarantee commercial success. Strategies need to be in place to ensure that technology successfully makes its journey to market. Here is where IP comes in. IP protection provides researchers with a period of exclusivity to get ahead of the competition. A 2023 study reported by the European Patent Office (EPO) found that start-ups with patents and trademarks were 10 times more successful in securing funding. The exclusivity afforded by IP protection will be attractive to investors, who will want to reap the rewards of their investment in a less competitive environment for at least a period of time. IP can also spur innovation, encouraging competitors to seek improvements and/or design-arounds to their competitor’s IP to enable them to customers a variety of technical solutions in the same space. Developing strategies to best protect innovation will be key to getting technology from the lab or “virtual” bench to market.

So if the Chancellor really wants to go “further and faster” to kick start the economy, it’s not just the much-touted transport links between Oxford and Cambridge that she needs to worry about. We need an ecosystem around the hubs of innovation to ensure that companies are supported to convert great science to tangible commercial results. Protecting intangible assets through IP will a key role in this.


This article was prepared by Hsu Min Chung (Partner, Chemistry & Materials), Craig Thomson (Partner, Life Sciences), Kerry Rees (Partner, Life Sciences) and Matt Cassie (Partner, AI)

[1] https://www.hp.com/hpinfo/abouthp/histnfacts/publications/garage/innovation.pdf

[2] https://www.economist.com/business/2016/01/16/clusterluck

[3] https://www.cgchomevideo.com/en-US/news-and-events/news/76/the-case-of-betamax-versus-vhs

Latest updates

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Read article

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

Often Copied, Never Equaled: When Do Everyday Items Become Subject of Copyright?

The  borderline between ‘pure’ works of art and mere utilitarian objects” –  Can iconic, yet everyday products be protected under copyright? The above question was posed by Advocate General in …

Read article

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details